Article Text

Download PDFPDF

LP-199 Medications given to patients with incomplete systemic lupus erythematosus
  1. Tatiana Panafidina,
  2. Tatiana Popkova,
  3. Liubov Kondrateva,
  4. Yulia Gorbunova,
  5. Anastasiia Shumilova and
  6. Alexandr Lila
  1. Systemic lupus erythematosus, V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation


Background Often, patients present with clinical symptoms and immunologic abnormalities suggestive of systemic lupus erythematosus(SLE), while not meeting classification criteria yet. This is referred to as incomplete SLE(iSLE). Timely treatment, however, is important to limit disease progression, and prevent organ damage and mortality. The aim of the study was to evaluate the therapy administered to patients diagnosed with iSLE.

Methods iSLE(n=60) was defined by rheumatologists as clinical diagnosis, not fulfilling ACR or SLICCcriteria and had no classification or specific symptoms of other rheumatic diseases. The majority of the iSLE patients were female (97%), aged 38[26–47]years. The median age of iSLE diagnosis was 33[25–42]years, disease duration was 12[2–39]months, 12(20%)pts had a disease duration of ≥5 years. The median SLEDAI-2K was 2[1–5] score, SDI – 0[0–0] score.

Results A large proportion of iSLE patients (55%) were prescribed hydroxychloroquine at a dose of 200 mg/day and oral corticosteroids (42%), the maximum dose of prednisolone was 15[6–40]mg/day. Five (8%) patients with iSLE were taking immunosuppressants: sulfasalazine-2(4%), methotrexate-1(2%), azathioprine-1(2%), and cyclophosphamide -1(2%). Six (10%) iSLE patients were taking biology: rituximab -1(2%), IL-6 inhibitor – 1(2%), intravenous human immunoglobulin – 4(7%). Other medicines: NSAIDs – 28%, vitamin D – 27%, course of antibiotics – 18%, low dose aspirin – 17%, anticoagulants – 10%, antipsychotics – 5%, eltrombopag and antihistamines – 2% each of patients.

Conclusions Although iSLE is sometimes considered a mild form of lupus, the clinical manifestations of iSLE can be significant. This may explain why many iSLE patients are treated with immunomodulatory medications.

  • iSLE
  • incomplete systemic lupus erythematosus
  • treatment of iSLE

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.